Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Lapo Alinari, MD, Beth Christian, MD, Bo Yu, Jungook Shin, Erin K Hertlein, PhD, Rosa Lapalombella, PhD, Fengting Yan, MD, PhD, Gregory Lesinski, PhD, Xiaoli Zhang, PhD, Gerard Lozanski, MD, Natarajan Muthusamy, PhD, David M. Goldenberg, ScD, MD, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD

Blood (2009) 114 (22): 1694.

https://doi.org/10.1182/blood.V114.22.1694.1694

Published: 2009

Journal Articles

Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCe™ SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells.

Sarwish Rafiq, Carolyn Cheney, Peter A Thompson, MD, FRACP, Tony Siadak, Paul Algate, Chuck Cerveny, John C. Byrd, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 1744.

https://doi.org/10.1182/blood.V114.22.1744.1744

Published: 2009

Journal Articles

A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP TM ) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.

Leslie Andritsos, MD, Richard R Furman, Ian W Flinn, Andres Foreno-Torres, M.D., Joseph M. Flynn, DO, MPH, FACP, Natarajan Muthusamy, PhD, Sarwish Rafiq, MS, Scott Stromatt, MD, John C. Byrd

Blood (2009) 114 (22): 3424.

https://doi.org/10.1182/blood.V114.22.3424.3424

Published: 2009

Journal Articles

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

Kami Maddocks, MD, Rosa Lapalombella, PhD, Kristie A Blum, MD, William Blum, MD, Beth B. Fischer, Natarajan Muthusamy, PhD, Mollie E. Moran, Donna Holtzapfel, NP, John C. Byrd, Amy J. Johnson, PhD, Leslie Andritsos, MD,

Blood (2009) 114 (22): 3446.

https://doi.org/10.1182/blood.V114.22.3446.3446

Published: 2009

Journal Articles

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

Farrukh Awan, MD, MS, Rosa Lapalombella, PhD, Rossana Trotta, PhD, Jonathan P Butchar, Ph.D., Bo Yu, Don Benson, MD, PhD, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Alan Jones, MD, MPH, Joseph M Flynn, David Jarjoura, Robert A. Baiocchi, MD, PhD, John Desjarlais, Susheela Tridandapani, Ph.D., Michael A. Caligiuri, M.D., Natarajan Muthusamy, PhD, John C. Byrd

Blood (2009) 114 (22): 3725.

https://doi.org/10.1182/blood.V114.22.3725.3725

Published: 2009

Journal Articles

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lapo Alinari, MD, Qing Liu, PhD, Ching-Shih Chen, PhD, Fengting Yan, MD, PhD, James T Dalton, PhD, Rosa Lapalombella, PhD, Xiaoli Zhang, PhD, Teresa Lin, BS, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 3728.

https://doi.org/10.1182/blood.V114.22.3728.3728

Published: 2009

Journal Articles

Transcriptional up-Regulation of IL-21 Receptor-α On CLL Cells by CpG685 through An NF-κB Mediated Pathway Provides a Rationale for Combination Strategies with IL-21.

Rebekah L. Browning, Shu-Huei Wang, PhD, Asha Ramanunni, Natarajan Muthusamy, PhD, John C. Byrd

Blood (2009) 114 (22): 2761.

https://doi.org/10.1182/blood.V114.22.2761.2761

Published: 2009

Journal Articles

Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells.

Erin K Hertlein, PhD, Georgia Triantafillou, Joshua Hessler, Xiaoli Zhang, David Jarjoura, David M. Lucas, PhD, Robert J Lee, Natarajan Muthusamy, PhD, David M Goldenberg, ScD, MD, John C. Byrd, MD

Blood (2009) 114 (22): 721.

https://doi.org/10.1182/blood.V114.22.721.721

Published: 2009

Journal Articles

Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma

Lapo Alinari, MD, Erin Hertlein, PhD, David M. Goldenberg, ScD, MD, Rosa Lapalombella, PhD, Fengting Yan, MD, PhD, Xiaoli Zhang, PhD, David M. Lucas, PhD, Natarajan Muthusamy, PhD, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD

Blood (2008) 112 (11): 886.

https://doi.org/10.1182/blood.V112.11.886.886

Published: 2008

Journal Articles

Arsenic Trioxide and Ascorbic Acid Enhances the Cytotoxicity of Hu1D10 towards CLL Cells.

Sabyasachi Biswas, PhD, Andrew P. Mone, MD, PhD, Chandan K. Sen, PhD, Natarajan Muthusamy, PhD, John C. Byrd, MD

Blood (2004) 104 (11): 3479.

https://doi.org/10.1182/blood.V104.11.3479.3479

Published: 2004

Journal Articles

Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells.

Xiaobin B. Zhao, MS, Sabyasachi Biswas, PhD, Andrew Mone, MD, PhD, Jeffrey Ledbetter, PhD, Martha Hayden Ledbetter, PhD, Laura Grosmaire, PhD, Erik Espling, PhD, Carolyn Cheney, Donn Young, PhD, Robert J. Lee, PhD, Natarajan Muthusamy, PhD, John C. Byrd, MD

Blood (2004) 104 (11): 2515.

https://doi.org/10.1182/blood.V104.11.2515.2515

Published: 2004

NARROW

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCe™ SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells.

A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP TM ) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Transcriptional up-Regulation of IL-21 Receptor-α On CLL Cells by CpG685 through An NF-κB Mediated Pathway Provides a Rationale for Combination Strategies with IL-21.

Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells.

Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma

Arsenic Trioxide and Ascorbic Acid Enhances the Cytotoxicity of Hu1D10 towards CLL Cells.

Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only